Network Pharmacology-Guided Phytochemical Polypharmacology: Integrating Molecular Mechanisms, Experimental Validation and Clinical Translation.
4 affiliations
- 1Department of Pharmacology, Jawaharlal Nehru Medical College, Adani Institute of Higher Education and Research, Wardha 442107, Maharashtra, India.
- 2Department of Paediatrics, Jawaharlal Nehru Medical College, Adani Institute of Higher Education and Research, Wardha 442107, Maharashtra, India.
- 3Department of Biochemistry, Jawaharlal Nehru Medical College, Adani Institute of Higher Education and Research, Wardha 442107, Maharashtra, India.
- 4Department of Anatomy, Jawaharlal Nehru Medical College, Adani Institute of Higher Education and Research, Wardha 442107, Maharashtra, India.
Abstract
Network pharmacology offers a systems-level framework for prioritising potential multi-target actions of phytochemicals, but predicted network convergence alone does not establish pharmacologically relevant polypharmacology. This structured narrative review evaluates curcumin, berberine, epigallocatechin-3-gallate (EGCG), and resveratrol as representative case studies, drawing on substantial mechanistic, pharmacokinetic, and translational literature. Evidence is appraised across computational prediction, biochemical interaction, cellular pathway modulation, target engagement or functional validation, in vivo pharmacology, and human evidence, with an emphasis on exposure compatibility. Across the four compounds, overlapping effects on inflammatory, metabolic, stress-response, and growth-regulatory pathways are supported predominantly by cellular and pathway-level studies. In contrast, direct target engagement, causal contribution, and clinically achievable exposure are less consistently demonstrated. Human pharmacokinetic and tissue-exposure studies show that systemic parent-compound concentrations may differ markedly from those used in mechanistic experiments, although local exposure and metabolites can modify this relationship. Clinical studies support selected pharmacodynamic or metabolic effects but do not establish that therapeutic benefit results from the simultaneous engagement of the broad, predicted target networks. Emerging computational, experimental, and delivery approaches can strengthen hypothesis prioritisation but do not replace mechanistic validation. We propose an exposure-aware, evidence-tiered framework in which clinically meaningful phytochemical polypharmacology requires convergence of achievable exposure, target engagement, causal pharmacodynamics, and clinical outcomes.
Related
- Prospective discovery of LasB inhibitors by integrating generative design, free energy ranking, and experimental validation
- MultiTargetDB: a comprehensive database of multitarget ligands for polypharmacology research and drug discovery
- PED in 2027: integrating experimental and predicted protein conformational ensembles at scale
- Modulating biochemical and phytochemical profiles in Lallemantia royleana callus culture via graphitic carbon nitride nano-elicitation
- Chemical profiling and multitarget computational screening reveal bioactive phytochemical scaffolds from Echiochilon pauciflorum stocks ex wight
BibTeX
@article{singh2026network,
title = {{Network Pharmacology-Guided Phytochemical Polypharmacology: Integrating Molecular Mechanisms, Experimental Validation and Clinical Translation.}},
author = {Saahil A Singh and Prabodh Wankhade and Rajesh Godvarthi and Rupesh Warbhe and Prashanth Khartade and Mohd Basheeruddin and Shilpa Narwade},
journal = {International journal of molecular sciences},
year = {2026},
month = sep,
doi = {10.3390/ijms27198683},
url = {https://europepmc.org/article/MED/42883928},
note = {CC BY},
}
RIS
TY - JOUR
TI - Network Pharmacology-Guided Phytochemical Polypharmacology: Integrating Molecular Mechanisms, Experimental Validation and Clinical Translation.
AU - Saahil A Singh
AU - Prabodh Wankhade
AU - Rajesh Godvarthi
AU - Rupesh Warbhe
AU - Prashanth Khartade
AU - Mohd Basheeruddin
AU - Shilpa Narwade
PY - 2026
DA - 2026/09/28
JO - International journal of molecular sciences
DO - 10.3390/ijms27198683
UR - https://europepmc.org/article/MED/42883928
AB - Network pharmacology offers a systems-level framework for prioritising potential multi-target actions of phytochemicals, but predicted network convergence alone does not establish pharmacologically relevant polypharmacology. This structured narrative review evaluates curcumin, berberine, epigallocatechin-3-gallate (EGCG), and resveratrol as representative case studies, drawing on substantial mechanistic, pharmacokinetic, and translational literature. Evidence is appraised across computational prediction, biochemical interaction, cellular pathway modulation, target engagement or functional validation, in vivo pharmacology, and human evidence, with an emphasis on exposure compatibility. Across the four compounds, overlapping effects on inflammatory, metabolic, stress-response, and growth-regulatory pathways are supported predominantly by cellular and pathway-level studies. In contrast, direct target engagement, causal contribution, and clinically achievable exposure are less consistently demonstrated. Human pharmacokinetic and tissue-exposure studies show that systemic parent-compound concentrations may differ markedly from those used in mechanistic experiments, although local exposure and metabolites can modify this relationship. Clinical studies support selected pharmacodynamic or metabolic effects but do not establish that therapeutic benefit results from the simultaneous engagement of the broad, predicted target networks. Emerging computational, experimental, and delivery approaches can strengthen hypothesis prioritisation but do not replace mechanistic validation. We propose an exposure-aware, evidence-tiered framework in which clinically meaningful phytochemical polypharmacology requires convergence of achievable exposure, target engagement, causal pharmacodynamics, and clinical outcomes.
SN - 1422-0067
ER -